Continuing review of an approved and ongoing study posing more than minimal risk that was initially approved by a convened IRB:

A. Must be conducted by a convened IRB.
B. Is not required unless additional risks have been identified.
C. Is limited to review of unanticipated problems.
D. Must occur within 12 months of the approval date.